Emerging sunshine rules obscure privacy rights for European healthcare professionals

1 June 2018
medical_legal_law_big

In an expert view piece, Ronald Wisor (above, left) and Hein van den Bos — partners at the global law firm Hogan Lovells — discuss the challenges created by Europe's evolving transparency laws.

The 2010 Physician Payments Sunshine Act created a new standard of transparency for financial relationships between pharmaceutical companies and health care professionals in the USA. Now, countries across Europe are following suit by rolling out their own 'sunshine' rules. But these rules differ from country to country, which means navigating a challenging regulatory patchwork of nation-specific regulations, managing press around existing relationships, and dealing with new costs related to compliance.

In some countries, sunshine rules are laid down in the law itself and there are penalties for non-compliance. But in other countries, the rules are established by industry or physician codes of conduct and it is softer regulation, often without any penalties. And in some other countries, there aren't really sunshine rules at all.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical